Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles
| dc.contributor.author | Yang, Shieh-Yueh | |
| dc.contributor.author | Chiu, Ming-Jang | |
| dc.contributor.author | Lin, Chin-Hsien | |
| dc.contributor.author | Horng, Herng-Er | |
| dc.contributor.author | Yang, Che-Chuan | |
| dc.contributor.author | Chieh, Jen-Jie | |
| dc.contributor.author | Chen, Hsin-Hsien | |
| dc.contributor.author | Liu, Bing-Hsien | |
| dc.date.accessioned | 2016-06-08T16:03:42Z | |
| dc.date.available | 2016-06-08T16:03:42Z | |
| dc.date.issued | 2016-06-08 | |
| dc.date.updated | 2016-06-08T16:03:43Z | |
| dc.description.abstract | Abstract Background It is difficult to discriminate healthy subjects and patients with Parkinson disease (PD) or Parkinson disease dementia (PDD) by assaying plasma α-synuclein because the concentrations of circulating α-synuclein in the blood are almost the same as the low-detection limit using current immunoassays, such as enzyme-linked immunosorbent assay. In this work, an ultra-sensitive immunoassay utilizing immunomagnetic reduction (IMR) is developed. The reagent for IMR consists of magnetic nanoparticles functionalized with antibodies against α-synuclein and dispersed in pH-7.2 phosphate-buffered saline. A high-Tc superconducting-quantum-interference-device (SQUID) alternative-current magnetosusceptometer is used to measure the IMR signal of the reagent due to the association between magnetic nanoparticles and α-synuclein molecules. Results According to the experimental α-synuclein concentration dependent IMR signal, the low-detection limit is 0.3 fg/ml and the dynamic range is 310 pg/ml. The preliminary results show the plasma α-synuclein for PD patients distributes from 6 to 30 fg/ml. For PDD patients, the concentration of plasma α-synuclein varies from 0.1 to 100 pg/ml. Whereas the concentration of plasma α-synuclein for healthy subjects is significantly lower than that of PD patients. Conclusions The ultra-sensitive IMR by utilizing antibody-functionalized magnetic nanoparticles and high-Tc SQUID magnetometer is promising as a method to assay plasma α-synuclein, which is a potential biomarker for discriminating patients with PD or PDD. | |
| dc.identifier.citation | Journal of Nanobiotechnology. 2016 Jun 08;14(1):41 | |
| dc.identifier.uri | http://dx.doi.org/10.1186/s12951-016-0198-5 | |
| dc.identifier.uri | http://rportal.lib.ntnu.edu.tw/handle/20.500.12235/78994 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.title | Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles | |
| dc.type | Journal Article |